Trial intelligence / Profile preview

Rapid vs Standard IC51 Regime for Japanese Encephalitis

NCT00595790Phase 3Completed

Sponsor
Valneva
Start
Sep 2005
Primary completion
Feb 2006
Modality
Vaccines & Immunotherapeutics
01

Overview

Phase 3, randomised, single-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (3 arms), sponsored by Valneva. Primary endpoint: Seroconversion Rate at Day 56. Started Sep 2005; status: completed.

02

Drugs

Japanese encephalitis inactivated vaccine
03

Conditions

Japanese encephalitis (JE)

Beyond the preview

Go deeper on NCT00595790.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00595790.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call